Even as everyone was going through the Science and Nature reviews of the rejected STAP papers this week, something else on the STAP front that happened last week. What’s up? Well, the STAP Nature papers are retracted, RIKEN CDB is going to be reorganized, RIKEN CDB has tried at least 22 times to make STAP …
Harvard STAP cell authors release new protocol, affirm belief in phenomenon Read More »
In a major first for the stem cell and regenerative medicine fields, a patient in Japan today received a pioneering transplant of a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells, also known by the acronym IPSC. This is the first ever iPS cell-based transplant into a human. The patient is …
Landmark: patient receives first ever iPS cell based transplant Read More »
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently …
ACT reinventing itself with new name Ocata Therapeutics Read More »
The reviews of a STAP paper submitted to and rejected by the journal Science in 2012 were posted at Retraction Watch yesterday. They filled in some gaps in the puzzle of the series of events that led to such flawed science being published in Nature in January 2014, but the reviews also raised more questions. Today, more STAP paper …
STAP papers blistered by Nature’s own reviewers were then accepted Read More »
Before the two STAP cell papers were published in Nature in January of 2014, much of the same data was reportedly submitted as single papers to other high-profile journals including Science. In these cases, the proto-STAP papers as we might call them were rejected. But why? Until now we largely could only speculate. However, the reviews …
Full Reviews of Rejected STAP Paper Point to Early Signs of Big Trouble Read More »
I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on …
Some diverse new stem cell papers worth a peek this weekend? Direct reprogramming hits crest: Generation of Multipotent Induced Neural Crest by Direct Reprogramming of Human Postnatal Fibroblasts with a Single Transcription Factor, Cell Stem Cell Hormone receptors in prostate cancer cells versus stem cells: Concise Review: Androgen Receptor Differential Roles in Stem/Progenitor Cells Including Prostate, Embryonic, Stromal, …
5 new cool stem cell papers worth a look for weekend reading Read More »
I am doing some polling on whether people who have finished graduate school would go again, why or why not, and what their current position is at this time. I found the responses to be surprising and interesting. Almost two-thirds of respondents indicated they would do grad school again if given a do-over. Despite all the …
In polling, most scientists would go to grad school again & here’s why or why not Read More »
The last two years at Nature Magazine have seen a surprising wave of paper retractions. In 2013 and now just so far in 2014, Nature has retracted a total of 14 papers. How unusual is that? Historically, Nature retracts relatively few papers, perhaps just under two per year on average. What the heck has been going on in 2013-2014? Let’s break it …
Could Nature’s 2-year torrent of paper retractions be a good thing? Read More »
By Zubin Master Scientist Yoshiki Sasai, age 52, committed suicide and was found dead on August 5, 2014. Sasai was deputy director of the Center for Developmental Biology (CDB) at RIKEN in Kobe, Japan, and coauthor on two recently retracted Nature papers about a reportedly easier way to make induced pluripotent stem cells. The papers …